Excessive accumulation of body fat triggers insulin resistance and features of the metabolic syndrome. Recently, evidence has accumulated that obesity, type 2 diabetes, and metabolic syndrome are associated with reduced levels of serum prolactin (PRL) in humans and rodents, raising the question of whether low PRL levels contribute to metabolic dysfunction. Here, we have addressed this question by investigating the role of PRL in insulin sensitivity and adipose tissue fitness in obese rodents and humans. In diet-induced obese rats, treatment with PRL delivered via osmotic mini-pumps, improved insulin sensitivity, prevented adipocyte hypertrophy, and reduced inflammatory cytokine expression in visceral fat. PRL also induced increased expression of Pparg and Xbp1s in visceral adipose tissue and elevated circulating adiponectin levels. Conversely, PRL receptor null mice challenged with a high-fat diet developed greater insulin resistance, glucose intolerance, and increased adipocyte hypertrophy compared with wild-type mice. In humans, serum PRL values correlated positively with systemic adiponectin levels and were reduced in insulin-resistant patients. Furthermore, PRL circulating levels and PRL produced by adipose tissue correlated directly with the expression of PPARG, ADIPOQ, and GLUT4 in human visceral and sc adipose tissue. Thus, PRL, acting through its cognate receptors, promotes healthy adipose tissue function and systemic insulin sensitivity. Increasing the levels of PRL in the circulation may have therapeutic potential against obesity-induced metabolic diseases. (Endocrinology 158: 56-68, 2017) 
A dipose tissue dysfunction is a hallmark of obesityinduced metabolic disorders and is also a feature of type 2 diabetes (T2D) and accelerated cardiovascular disease. Adipose tissue functions as an energy reservoir that is central for maintaining whole-body glucose and lipid homeostasis. In obesity, excessive lipid accumulation in adipocytes triggers mechanisms that result in systemic insulin resistance, including impaired adipogenesis (1), altered adipokine secretion, inflammation, fibrosis, reduced angiogenesis, excess free fatty acid release, and ectopic fat deposition (2, 3) . Visceral adipose tissue (VAT) expansion is particularly associated with increased risk of metabolic disorders, whereas sc adipose tissue (SAT) accumulation has little or no negative metabolic impact and may even be protective (4, 5) . Identifying factors that promote adipose tissue fitness may be of therapeutic value against insulin resistance and its associated metabolic diseases. Here, we suggest that one such factor is the hormone prolactin (PRL).
PRL is a multifunctional hormone with effects on metabolism. Increased PRL levels can stimulate food intake by promoting leptin resistance (6) (7) (8) (9) (10) and enhance body weight and adiposity (6, 7, (11) (12) (13) (14) in rats and mice. Some of these actions were evaluated in females and may not occur in males (14, 15) , consistent with the concept that they are part of the metabolic adaptations occurring during pregnancy and lactation, when high PRL levels, leptin resistance, hyperphagia, increased body weight, and adiposity coincide to increase nutrient availability to favor offspring development and survival (16) . However, PRL can have an adverse impact on metabolism in scenarios of pathological hyperprolactinemia (prolactinomas). Studies, in both men and women, show that the occurrence of prolactinomas associates with higher prevalence of obesity and metabolic alterations such as dyslipidemia, glucose intolerance, and insulin resistance, and these alterations are reduced by lowering PRL levels with dopamine agonists (17) (18) (19) (20) (21) . However, dopamine agonists may also increase body weight in patients with prolactinomas (21, 22) , and there are studies in which body mass index (BMI) and metabolic improvement do not directly correlate with the reduction in PRL levels (23) (24) (25) . In support of high systemic PRL being deleterious for metabolic homeostasis, PRL levels above 200 ng/mL and up to 4000 ng/mL in female mice for several months correlate with increased food intake, higher body weight and adiposity, glucose intolerance, and insulin resistance (14, 26) .
PRL operates at different levels to regulate metabolism. It stimulates b-cell proliferation, survival, and insulin secretion in rodents and humans (27, 28) and promotes liver insulin sensitivity in rodents (29) . PRL receptors are expressed on adipocytes from humans, rats, and mice, and PRL is produced by human adipose tissue (30) , where it contributes to adipogenesis and inhibits lipolysis (31) (32) (33) . PRL stimulates also the formation and function of brown fat tissue in newborn rodents (34) . Finally, the beneficial effect of adequate PRL levels is highlighted by recent large cohort studies in men and women showing reduced levels of serum PRL in patients having glucose intolerance, T2D, and insulin resistance (35) (36) (37) and in children with metabolic syndrome and obesity (38) , suggesting thereby that lower PRL levels contribute to disruption of metabolic homeostasis.
Here, we evaluated whether PRL promotes insulin sensitivity and adipose tissue metabolic health in obese rodents and whether in humans circulating and adipose tissue-produced PRL correlate with metabolic fitness markers systemically and in adipose tissue. We demonstrate that PRL administration counteracts obesityinduced insulin resistance and adipose tissue dysfunction in obese rats, whereas obese mice lacking PRL receptors show enhanced insulin resistance and unhealthy adipose tissue expansion. In agreement, PRL levels are reduced in insulin-resistant patients compared with insulin-sensitive ones and correlate directly with the levels of circulating adiponectin and with the expression of makers of fat fitness in both VAT and SAT. Our findings support the concept that lower concentrations of serum PRL in obesity have deleterious consequences for metabolic homeostasis and that increasing PRL levels may be a therapeutic aid against obesity-induced adipose tissue dysfunction and insulin resistance.
Materials and Methods

Experimental procedures in rats
Male Wistar rats bred for several years at our animal facility (the vivarium of the Institute of Neurobiology of the Universidad Nacional Autónoma de México [UNAM]) were housed at 22°C on a 12-hour light, 12-hour dark cycle with free access to food and water. Four-week-old rats were fed either a control diet (CD) (Laboratory rodent Diet 5001; LabDiet) or a high-fat diet (HFD) (Open Source Diet D12492; Research Diets) for 8 weeks. In the CD, 28%, 13.5%, and 58% of calories come from proteins, fat, and carbohydrates, respectively, whereas in the HFD, 20%, 60%, and 20% of calories come from proteins, fat, and carbohydrates, respectively. The fat source for both the CD and HFD is largely pig fat or lard. In the HFD, carbohydrates come from maltodextrin and sucrose and proteins from casein, whereas the CD contains oats, wheat, corn, soybean meal, wheat germ, cane molasses, fish meal, dried brewer's yeast, and porcine meat meal as sources of carbohydrate and protein. Thus, the CD is a balanced meal, whereas the HFD is high in fat and in simple sugars. After 4 weeks on the CD or HFD, rats were implanted sc or not with Alzet osmotic minipumps (DURECT Corp) releasing 0.16-mg/kg $ d ovine PRL (Sigma-Aldrich) for 28 days. For this purpose, rats were anesthetized with ether inhaled for approximately 2 minutes, using an ether-soaked cotton ball placed at the bottom of a 50-mL conical tube (a new cotton was used for each animal and the cotton was never in direct contact with the animal), and the pumps were implanted sc in less than 2 minutes. To avoid stress-induced alterations in the amount of PRL released, animals were handled daily for 7 days before euthanization by CO 2 inhalation and decapitation. All studies were approved by the Bioethics Committee of the Institute of Neurobiology of the UNAM (protocol numbers 033 and 075), which complies with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (8th ed, National Academy Press).
Serum measurements
Rat PRL was evaluated by RIA. However, because the RIA for rat PRL does not detect ovine PRL, we used the Noble rat lymphoma (Nb2) assay to quantify the circulating levels of ovine PRL released by the osmotic minipump in the pumpimplanted rats. This is a standardized method based on the proliferative response of Nb2 lymphoma cells to PRL (39) . The Nb2 assay detects all PRLs (rat and ovine); therefore, we made this assay specific to ovine PRL by using antiovine PRL antibodies (National Hormone and Peptide Program; catalog number C-3581016789, Research Resource Identifier RRID AB_2629483) (see antibody in Table 1 ), that do not cross-react with rat PRL. Therefore, the difference in Nb2-bioactivity between the absence and presence of antiovine PRL quantified the levels of ovine PRL in rat serum. Rat adiponectin serum levels were measured using an ELISA kit (Millipore).
Insulin tolerance test (ITT)
The ITT was performed in rats 3 weeks after delivering PRL via osmotic pumps (7 wk after the start of the CD or HFD). Glucose levels were measured with a glucometer in tail vein blood samples obtained with a lancet needle, before or 15, 30, 60, and 120 minutes after an ip injection of 0.75-U/kg insulin (Humulin R; Eli Lilly).
Adipose tissue histology
Subcutaneous inguinal and epididymal (visceral) adipose tissues from rats were fixed in 10% formalin, and sections of 10 mm were stained with hematoxylin and eosin. Adipocyte size was determined by calculating the mean adipocyte area from 9 fields per animal in 6-10 rats per group using the ImageJ software (https://www.imagej.nih.gov). The relative adipocyte number was calculated by dividing the fat pad weight by the mean adipocyte area in that fat depot.
Real Time-quantitative PCR (qPCR)
Adipose tissues were frozen in liquid nitrogen and stored at 280°C. Total RNA was extracted using the TRIzol reagent (Invitrogen), and cDNA was synthesized using the high-capacity cDNA reverse transcription kit (Applied Biosystems). PCR products were detected and quantified in a Bio-Rad CFX96 Real-Time System (Bio-Rad Laboratories), using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) in a final reaction volume of 10 mL containing template and 0.5mM each of the primer pairs for rat ( 
Statistics
Statistical data analysis was performed using SigmaStat 3.5 (Systat Software, Inc). Differences between groups were evaluated by two-way ANOVA followed by the Bonferroni's post hoc comparison test. Body weight and ITT curves were evaluated using repeated measures ANOVA. The threshold for significance was set at P , .05.
Experimental procedures in mice
C57BL/6 Prlr1/2 mice were purchased from The Jackson Laboratory, and the colony was expanded and maintained for several generations before animals were used in our experiments. Animals were housed at 22°C on a 12-hour light, 12-hour dark cycle with free access to food and water. Eight-to 10-week-old male mice were fed a CD (Laboratory rodent Diet 5001; Lab-Diet) or a HFD (Open Source Diet D12492; Research Diets) for 8 weeks. To avoid stress-induced alterations in the amount of PRL released, animals were handled daily for 7 days before euthanization by CO 2 inhalation and decapitation. All studies were approved by the Bioethics Committee of the Institute of Neurobiology of the UNAM (protocol numbers 033 and 075), which complies with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (8th ed, National Academy Press).
Serum measurements
Mouse adiponectin serum levels were measured using an ELISA kit (Millipore).
ITT and glucose tolerance test (GTT)
ITT and GTT were performed in mice after 6 and 7 weeks, respectively, of CD or HFD. Glucose levels were measured with a glucometer in tail vein blood samples obtained with a lancet needle, before or 15, 30, 60, 90, and 120 minutes after an ip injection of 0.75-U/kg insulin (Humulin R; Eli Lilly) for the ITT, or 2 g/kg of 50% dextrose (PiSA Pharmaceuticals) for the GTT.
Adipose tissue histology
Subcutaneous inguinal and epididymal (visceral) adipose tissues from mice were fixed in 10% formalin, and sections of 7 mm were stained with hematoxylin and eosin. Adipocyte size was determined by calculating the mean adipocyte area from 9 fields per animal in 10-13 mice per group using the ImageJ software (https://www.imagej.nih.gov). The relative adipocyte number was calculated by dividing the fat pad weight by the mean adipocyte area in that fat depot.
qPCR
Adipose tissues were frozen in liquid nitrogen and stored at 280°C. Total RNA was extracted using the TRIzol reagent (Invitrogen), and cDNA was synthesized using the high-capacity cDNA reverse transcription kit (Applied Biosystems). PCR products were detected and quantified in a Bio-Rad CFX96 RealTime System (Bio-Rad Laboratories), using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) in a final reaction volume of 10 mL containing template and 0.5mM each of the primer pairs for mouse (Pparg, Il1b, Ccl2, Xbp1s, and Prlr) genes. TATA box-binding protein (Tbp) was used as housekeeping gene. Primer sequences are shown in Supplemental Table 1 .
Statistics
Statistical data analysis was performed using SigmaStat 3.5 (Systat Software, Inc). Differences between groups were evaluated by two-way ANOVA followed by the Bonferroni's post hoc comparison test. Body weight, ITT, and GTT curves were evaluated using repeated measures ANOVA. The threshold for significance was set at P , .05. Table 2 shows the clinical and biochemical characteristics of the subjects studied. Lean (BMI , 25), overweight (BMI 5 25-29.9), and obese (BMI $ 30) mestizo male subjects, undergoing . Fifty-four subjects were identified as candidates and signed the informed consent to participate. Serum samples were collected before surgery, and omental VAT and abdominal SAT samples were then obtained. Later, patients having PRL levels above basal values of 20 mg/L (n 5 27) were excluded from the analysis, leaving 27 study subjects. Because PRL is a "stress hormone," we were concerned that values of PRL in these patients could be influenced by a stress-related confounding factor that could bias our analysis. The excluded patients were from both, insulin resistant (12 subjects), and insulin sensitive (15 subjects) groups.
Experimental procedures involving human samples
Serum measurements
Human adiponectin serum levels were measured using ELISA kits (Millipore). Human PRL and insulin were measured by the Immulite 1000 Immunoassay Analyzer (Siemens), and glucose levels were evaluated by a colorimetric assay (Cayman Chemical).
qPCR Adipose tissues were frozen in liquid nitrogen and stored at 280°C. Total RNA was extracted using the TRIzol reagent (Invitrogen), and cDNA was synthesized using the high-capacity cDNA reverse transcription kit (Applied Biosystems). PCR products were detected and quantified in a Bio-Rad CFX96 RealTime System (Bio-Rad Laboratories), using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) in a final reaction volume of 10 mL containing template and 0.5mM each of the primer pairs for human (ADIPOQ, PPARG, SLC2A4
[GLUT4], and PRLR) genes. 18S rRNA was used as housekeeping gene. Primer sequences listed in Supplemental Table 1 .
Statistics
Statistical data analysis was performed using SigmaStat 3.5 (Systat Software, Inc) and Microsoft Excel XLSTAT. Differences between 2 groups were evaluated by the Student's t test, and those between 3 or more groups by one-way ANOVA followed by the Bonferroni's post hoc comparison test. Spearman analysis for nonparametric data was used to evaluate correlations between serum levels of PRL and insulin, adiponectin, homeostasis model of insulin resistance (HOMA-IR), and gene expression levels in adipose tissue. The threshold for significance was set at P , .05.
Results
PRL treatment improves insulin sensitivity in dietinduced obese rats
Confirming our previous findings that circulating levels of PRL are reduced in obese rodents (40) , after 8 weeks on a HFD, male rats showed lower serum PRL levels than animals fed a CD ( Figure 1A ).To explore whether reduced serum PRL levels contribute to the metabolic alterations seen in obesity, we increased systemic PRL with osmotic minipumps delivering the hormone during the last 4 weeks of the 8-week dietary intervention. PRL levels were increased to 4-6 times those in nontreated rats ( Figure 1A ). Although body weight and food consumption were unaltered by PRL treatment (Figure 1 , B and C), elevating systemic PRL levels in HFDfed animals improved metabolic responses, as evidenced by an enhanced insulin-induced, glucose-lowering effect during an ITT compared with animals on a HFD without PRL treatment ( Figure 1D ). In CD-fed animals, PRL treatment had no effect on insulin sensitivity ( Figure 1D ).
PRL prevents visceral adipocyte hypertrophy in obese rats
In the context of obesity, insulin sensitivity is attributed to a healthy expansion of the adipose tissue (1, 2, 41 ). This idea prompted us to evaluate whether PRL improves insulin sensitivity by promoting adipose tissue functionality. In HFD-fed animals, PRL treatment increased adipose tissue mass by 20% in the VAT and by 30% in the SAT depots beyond the increases induced by the HFD alone (Figure 2, A and D) . This increase in adipose tissue mass was not reflected on body weight, because it represents only a 2% increase in total body mass. Compared with CD-fed animals, the number of adipocytes was greater in HFD-fed rats and was further elevated by PRL by 21% and 37% in SAT and VAT, respectively ( Figure 2 , B and E). Moreover, PRL treatment also reduced adipocyte hypertrophy in HFD-fed rats exclusively in VAT, whereas adipocytes in SAT of HFD-fed rats were the same size with and without PRL treatment ( Figure 2, C and F) . Under CD conditions, PRL treatment had no effect on adipose tissue mass, adipocyte number, or size ( Figure 2 , A-F). Because hypertrophic fat cells are believed to be metabolically dysfunctional and adipocyte hyperplasia is a healthier mechanism for increasing fat storage (2), these findings suggest that PRL can promote a healthier form of adipose tissue expansion under obesity conditions.
PRL increases Pparg and Xbp1s expression in visceral fat, reduces adipose tissue inflammation, and promotes adiponectin secretion We next investigated the mechanisms that could mediate the beneficial actions of PRL on insulin sensitivity and adipose tissue expansion. In vivo, under HFD conditions PRL increased the expression of Pparg in the VAT but not in the SAT (Figure 2, G and H) .
Increased inflammation is characteristic of fat tissue in obesity and has been shown to contribute to insulin resistance (42) . PRL has been reported to exhibit both pro-and antiinflammatory actions in different cell types (43) . PRL administration reduced by 50% the expression of Il1b in VAT from both CD-and HFD-fed animals ( Figure 2G ) and also reduced the expression of Ccl2 in SAT from HFD-fed animals ( Figure 2H ).
The beneficial metabolic effects observed after elevating PRL levels in animals with HFD-induced obesity resemble those of adiponectin, an adipokine that is insulin sensitizing, proadipogenic, and antiinflammatory (44) . Administration of PRL increased circulating adiponectin levels in rats on both the CD and HFD by 20% and 36%, respectively ( Figure 2I) . Recently, the transcription factor Xbp1 has been identified as a PRL target in the mammary gland fat pad (45) , and the spliced form of Xbp1 has been shown to mediate increased adiponectin secretion by fat tissue in vivo (46) . PRL treatment resulted in increased Xbp1s expression in the VAT of animals under both CD and HFD conditions ( Figure 2J ), implying that Xbp1s may contribute to PRL effects on adiponectin.
The preferential effect of PRL treatment on VAT in the rats (reducing adipocyte hypertrophy and increasing Pparg and Xbp1s expression) may be explained by the increased expression of PRL receptors in adipose cells from this depot (47) . Interestingly, most of the effects of PRL on adipose tissue were observed under HFD feeding conditions. To explore whether the HFD could induce PRL receptor expression in fat thereby increasing PRL sensitivity, we evaluated the mRNA expression of the Prlr in the adipose tissue of rats under CD or HFD feeding conditions. We observed that Prlr expression is not changed by the HFD or by PRL treatment in either VAT or SAT (Supplemental Figure 1) . Similar results were observed in adipose tissue from CD vs HFD-fed mice and from lean vs overweight/obese humans (Supplemental Figure 1) .
PRL receptor-null mice under a HFD develop aggravated metabolic alterations
To further explore the role of PRL in metabolic health in obesity, Prlr2/2 mice (on a C57BL/6 background) were fed a HFD for 8 weeks and studied for metabolic parameters. Prlr2/2 mice gained more weight when fed a HFD ( Figure 3A ) and exhibited greater fat mass (Figure 3 , B and C). This expansion of fat mass induced by the Prlr deletion was the result of enhanced adipocyte hypertrophy (Figure 3 , D and E) in both fat depots with no significant change in adipocyte number per fat pad (Figure 3 , F and G). Prlr2/2 mice on a HFD showed exacerbated insulin Figure 1 . PRL treatment promotes insulin sensitivity in obese rats. Serum PRL levels after 8 weeks of CD or HFD in the absence or presence of osmotic minipumps delivering PRL during the last 4 weeks (n 5 5-7) (A). White bars represent rat endogenous PRL (rPRL) measured by RIA; black bars represent ovine PRL (oPRL) from pumps quantified by Nb2 assay. Body weight (n 5 7-14) (B), average food consumption (n 5 6-7) (C), and ITT (n 5 6-11) (D) at week 7 of the CD or HFD in rats treated or not with PRL. Data are mean 6 SEM; *, P , .05 vs respective CD or CD1PRL; &, P , .05 vs respective diet without PRL. Statistically significant differences were determined with two-way ANOVA (A and C) or repeated measures ANOVA (B and D), followed by the Bonferroni's post hoc test.
resistance and glucose intolerance compared with wildtype mice (Prlr1/1) on the same diet ( Figure 3, H and I ). Inflammatory markers (Il1b and Ccl2) and serum adiponectin levels were not different between genotypes or diets in Prlr2/2 vs Prlr1/1 mice (Supplemental Figure 2) . PRL serum levels in patients associate positively with adiponectin levels and are reduced in insulinresistant subjects Establishing a correlation between PRL actions in rodent models and humans would support our hypothesis that circulating PRL plays a protective role against adipose tissue and metabolic dysfunction. To this end, we evaluated 27 lean, overweight, and obese male patients (characteristics in Table 2 ) and analyzed their circulating PRL levels, metabolic parameters, and markers of adipose tissue functionality. Lean, overweight, and obese groups did not differ in age, glucose, adiponectin or PRL levels. However, overweight and overweight plus obese groups had higher insulin levels and HOMA-IR values than the lean group (Table 2) . In this population, serum PRL correlated inversely with serum insulin levels ( Figure 4A ) and HOMA-IR ( Figure 4B ) and positively with circulating adiponectin levels ( Figure 4C ). As expected, when the subjects were divided into insulin-sensitive and insulinresistant groups (HOMA-IR cutoff 5 3.0) (48), insulinresistant subjects had a higher BMI (Table 3) . Interestingly, the insulin-resistant subjects showed significantly (P 5 .03) Figure 2 . PRL treatment improves adipose tissue fitness in obese rats. VAT and SAT weight normalized to body weight (n 5 7-13) (A and D), relative adipocyte number per fat depot (n 5 6-10) (B and E), and representative sections of adipose tissue stained by hematoxylin and eosin to show adipocyte size (C and F). Graphs indicate quantification of adipocyte size in 9 fields per adipose tissue in 6-10 animals per group. Gene expression in VAT and SAT analyzed by qPCR (n 5 7-13) (G and H). Serum adiponectin levels quantified by ELISA (n 5 7-11) (I) and qPCR evaluation of Xbp1s in VAT (n 5 5-6) (J). All evaluations were made after 8 weeks of the dietary intervention in the absence or presence of osmotic minipumps delivering PRL during the last 4 weeks. Data are mean 6 SEM; *, P , .05 vs respective CD or CD1PRL; &, P , .05 vs respective diet without PRL. Statistically significant differences were determined with two-way ANOVA, followed by the Bonferroni's post hoc test. doi: 10.1210/en.2016-1444 press.endocrine.org/journal/endolower serum PRL levels than those who were insulin sensitive (Table 3) . However, as mentioned before, when separated by BMI, overweight or obese groups did not show lower serum levels of PRL compared with the lean group ( Table 2 ), indicating that reduced circulating PRL correlates with insulin resistance but not with obesity itself. Moreover, when subjects were divided by their circulating PRL levels, the higher PRL group showed reduced insulin resistance (P 5 .005) and increased adiponectin levels (P 5 .004) but similar BMI (Table 3) .
PRL serum levels and PRL produced in adipose tissue positively associate with expression of adipose tissue fitness markers The relationship between PRL and adipose tissue fitness was analyzed further by using VAT and SAT biopsies from lean, overweight, and obese patients (n 5 15) undergoing abdominal surgery, and their circulating and adipose tissue PRL levels were evaluated for correlations with the expression of PPARG, ADIPOQ, and GLUT4 in the fat tissue samples. Consistent with PRL promoting adipose tissue metabolic fitness, serum PRL levels correlated directly with the expression of ADIPOQ in both VAT and SAT, of PPARG in VAT, and of GLUT4 in SAT ( Figure 5 , A and C). Moreover, PRL is produced by human adipose tissue, where it may act as an autocrine/paracrine factor (30) . We found that PRL mRNA levels in adipose tissue correlated positively with the expression of ADIPOQ and GLUT4 in SAT but not in VAT ( Figure 5, B and D) . These results suggest that both systemic PRL and PRL produced locally by the adipose tissue promote insulin sensitivity and adipose tissue metabolic homeostasis in humans. Graphs indicate quantification of adipocyte size in 9 fields per adipose tissue in 10-13 animals per group. Relative adipocyte number per adipose depot (n 5 10-13) (F and G). ITT after 7 weeks on CD or HFD (n 5 11-13) (H). GTT after 6 weeks on CD or HFD (n 5 24-29) (I). Data are mean 6 SEM; *, P , .05 vs respective CD; &, P , .05 vs Prlr1/1 on HFD. Statistically significant differences were determined with two-way ANOVA (B-G) or repeated measures ANOVA (A, H, and I), followed by the Bonferroni's post hoc test.
Discussion
During obesity, the inability of adipose tissue to maintain its functionality while storing nutrient surplus triggers insulin resistance and multiple metabolic diseases. Conversely, a healthy expansion of adipose tissue maintains and can even restore whole-body insulin sensitivity (41) . Our study demonstrates that the hormone PRL promotes insulin sensitivity and the healthy expansion of adipose tissue and that these effects become apparent in both rodents and humans during obesity and insulin resistance, conditions that associate with low circulating PRL levels (35) (36) (37) (38) 40) . Mechanisms for the beneficial effects of PRL may include the ability to increase Pparg and Xbp1s expression and adiponectin secretion, as well as reducing adipocyte hypertrophy, increasing adipocyte hyperplasia, and reducing inflammation of adipose tissue. Also, other known effects of PRL may contribute to the overall beneficial effect of the hormone on metabolic homeostasis. In particular, PRL promotes b-cell function, not only in rodents but also in humans (27, 28) , and stimulates insulin sensitivity in liver of mice, where overexpression of the Prlr promotes insulin sensitivity, whereas liver-specific deletion of the Prlr increases insulin resistance (29) . Thus, together, these results imply that elevating the levels of PRL may have therapeutic value against obesityinduced metabolic dysfunction.
In obesity, excess fat is stored in existing adipocytes (hypertrophy) or in new fat cells (hyperplasia) generated from precursor cells by the process of adipogenesis (2, 3) . Hyperplasia is generally regarded as a relatively benign and perhaps even protective mechanism of adipose tissue expansion (2, 3), whereas deficient adipogenesis and exaggerated adipocyte hypertrophy are linked to adipose tissue dysfunction and metabolic syndrome (1, 49) . Here, we showed that PRL treatment stimulates adipocyte hyperplasia in VAT and SAT and reduces adipocyte hypertrophy in VAT of obese, insulin-resistant rats. Consistent with this observation, in the absence of PRL signaling (Prlr2/2 mice), diet-induced obesity resulted in a greater level of adipocyte hypertrophy in both fat depots that is associated with increased insulin resistance and glucose intolerance. The beneficial effects of PRL likely involve a direct action on adipocytes. PRL receptors are expressed in fat (50, 51) , both in adipocyte precursor cells and mature adipocytes (47) , and their levels are higher in visceral than in sc fat cells (47) . In addition, Prlr expression increases in the 3T3-L1 cell line during differentiation to adipocytes, and Figure 4 . Serum PRL levels associate with insulin sensitivity and adiponectin levels in human subjects. Correlation analysis of serum PRL with circulating insulin (A), HOMA-IR (B), and adiponectin levels (C) from lean, overweight, and obese male subjects. Here, we show that PRL promotes Pparg expression only in VAT and exclusively under HFD conditions. In view of the known ability of PPARg to improve insulin sensitivity (53) , it is likely to mediate the PRL protective effects. PPARg induces the expression of adiponectin (54) , an adipokine promoting insulin sensitivity in rodents and humans (55) . We found that elevating PRL in serum increases circulating adiponectin levels in rats under both control and HFD conditions. However, PRL stimulated Pparg expression only under HFD conditions, so the increase in adiponectin levels induced by PRL under CD likely involves other factors. One such factor may be Xbp1s, a transcription factor activated by PRL in mammary adipose tissue during lactation (45) . We found that PRL up-regulates Xbp1s in the VAT of rats under both CD and HFD feeding, Xbp1s induces adipogenesis via the transcriptional activation of Cebpa and Pparg (56, 57) and improves glucose tolerance and insulin sensitivity in lean and obese mice by increasing adiponectin secretion (46) .
It is puzzling that PRL treatment increases Xbpl levels in adipose tissue under both CD and HFD but increases Pparg only under HFD. Several studies have shown that many PPARg effects occur in association with obesity or HFD conditions (58) (59) (60) (61) . One mechanistic explanation for this is that visceral fat (but not SAT) from obese mice is more sensitive to PPARg agonists (rosiglitazone) (59) . Enhanced sensitivity results from increased expression of ubiquitin hydrolase/ligase ubiquitin C-terminal esterase L1 in visceral fat of obese mice and humans. Ubiquitin hydrolase/ligase ubiquitin C-terminal esterase L1 facilitates the proteasomal degradation of the PPARg heterodimerization partner retinoid X receptor a (RXRa), promoting increased PPARg-RXRb heterodimerization, which is less sensitive to transcriptional repression by silencing mediator of retinoid and thyroid hormone receptors than PPARg-RXRa. Thus, the reduced RXRa to RXRb ratio increases PPARg transcriptional activity (59), thereby promoting Cebpa expression and initiating the positive feedback loop between these 2 factors to mutually increase each other's expression. Accordingly, by favoring the action of PPARg agonists or activators, the obese condition provides a plausible explanation for the preferential effects of PRL treatment under HFD.
In our study, increasing serum PRL to levels (60-80 ng/mL) equivalent to those reported in male rats at circadian peaks (62) or in response to stress (63, 64) elevated systemic adiponectin. This implies that PRL at a relatively high concentration but within a physiological range found in female reproductive states may protect against metabolic dysfunction by increasing circulating adiponectin. However, contrary to this proposal, PRL reduces adiponectin secretion by adipose tissue in culture (65) and transgenic female (but not male) mice overexpressing PRL and having PRL serum levels (.250 ng/mL, at the high end of the normal range found during pregnancy and lactation), show lower systemic adiponectin values (65) . Although the differences in in vitro vs in vivo conditions, gender, physiological state, and PRL concentration may contribute to these discrepancies, clinical work supports our proposal. Clinical studies demonstrate that circulating PRL positively correlates with insulin sensitivity (36, 38) and with serum adiponectin in males (current findings) and in females with polycystic ovary syndrome (66) .
The inhibition of proinflammatory mediators is another way by which PRL may improve insulin sensitivity and fat fitness. In agreement with the antiinflammatory effects of PRL in other rodent models of disease (67), we found that PRL treatment reduces the expression of Il1b and Ccl2 in VAT and SAT, respectively, and both IL-1b and CCL2 contribute to inflammation-mediated insulin resistance and adipose tissue dysfunction in obesity (68, 69) .
Consistent with our observations in Prlr2/2 mice, mice deficient in PRL (on a C57BL/6 strain) fed a CD have normal adipose tissue mass and unaltered metabolic phenotype (70) . Although insulin sensitivity and adipose tissue fitness have not been evaluated in PRL null mice under a HFD, we show here that Prlr2/2 mice on a HFD develop increased obesity, exacerbated glucose intolerance, insulin resistance, and enlarged adipocytes. These findings confirm the beneficial actions of PRL on metabolic and adipose tissue function and show that its effects become evident during obesity. However, in apparent contradiction to our findings, Prlr2/2 mice on a 129/SvJ genetic background display milder obesity and no insulin resistance in response to a HFD (71) , which prompts to the emergence of beige/ brite adipocytes in white fat. The 129/SvJ strain is intrinsically less prone to diabetes and HFD-induced obesity than the C57BL/6 strain (72). Its reduced susceptibility involves increased intermuscular deposits of brown adipocytes (72), higher thermogenic capacity, augmented beiging potential, and distinct inflammatory pathways in the adipose tissue and gut microbiota environments (73, 74) . The aggravated metabolic alterations found in the present study in Prlr2/2 mice of the C57BL/6 strain were consistent with the fact that no beige adipocytes could be detected in SAT or VAT under HFD conditions (Figure 3, D and E) .
The above information makes clear that in rodents, as in humans, metabolic alterations depend on genetically associated risk and protective factors and that these factors are able to influence the outcome of PRL metabolic effects. However, our conclusion that the absence of PRL action in obesity has negative metabolic consequences that can be counteracted by increasing PRL levels, is supported by clinical data. Low PRL press.endocrine.org/journal/endolevels associate with glucose intolerance, insulin resistance, obesity, and T2D in adults (35) (36) (37) and with metabolic syndrome in children (38) . Here, we extend these findings by showing that insulin-sensitive male subjects have PRL values higher than those in insulin-resistant patients, regardless of their BMI (within the 19-36 range), and that patients' serum PRL levels associate positively with circulating adiponectin levels and with the expression of adipose tissue fitness markers, including ADIPOQ, PPARG, and GLUT4. Furthermore, our work supports the role of PRL as a local regulator of human adipose tissue (30) by showing that PRL synthesis in SAT correlates with the expression of ADIPOQ and GLUT4 in this adipose depot. In summary, the present study shows that PRL protects against obesity-induced insulin resistance by promoting the healthy expansion and metabolic fitness of adipose tissue via mechanisms that include increased levels of Xbp1s, Pparg, and adiponectin in fat. Given that low circulating PRL correlates with disrupted metabolic homeostasis in patients, restoring or elevating PRL levels may help reduce metabolic dysfunction in normal or obese individuals with insulin resistance. Our work expands the knowledge of PRL effects in physiological states beyond pregnancy and lactation, and highlights the need for a better understanding of its role in regulating metabolic homeostasis in both females and males.
